<DOC>
	<DOC>NCT00002401</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients. The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).</brief_summary>
	<brief_title>A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients</brief_title>
	<detailed_description>In this open-label pilot study, patients are randomized to 1of the following 4 arms for 24 weeks: Arm 1 (40 patients): DLV plus ZDV plus IDV. Arm 2 (40 patients): DLV plus IDV plus 3TC*. Arm 3 (40 patients): DLV plus ZDV plus IDV plus 3TC. Arm 4 (40 patients): ZDV plus IDV plus 3TC. - Dose determined by body weight. Patients may opt to continue on study for 24 additional weeks at the discretion of the investigator.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Prior Medication: Allowed: Less than 1 month prior treatment with zidovudine. Exclusion Criteria Prior Medication: Excluded: Prior indinavir. Prior lamivudine. Prior protease inhibitors. Prior nonnucleoside reverse transcriptase inhibitors. 1 month or more prior zidovudine. 1. HIV1 positive. CD4 coun tis above 50. HIV1 RNA levels greater than 20,000.</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA, Viral</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
</DOC>